SureTrader
Home > Boards > US Listed > Biotechs >

Inovio Pharmaceuticals, Inc. (INO)

INO RSS Feed
Add INO Price Alert      Hide Sticky   Hide Intro
Moderator: Ubertino
Search This Board: 
Last Post: 1/14/2018 8:42:19 PM - Followers: 410 - Board type: Free - Posts Today: 0

Logo: Inovio

www.inovio.com/

http://finance.yahoo.com/q/ks?s=INO

http://finance.aol.com/company/inovio-biomedical-corporation/ino/ase/institutional-ownership

F
ebruary 12, 2014 Inovio CEO Dr. Joseph Kim rings bell to open trading on NYSE- http://www.youtube.com/watch?v=95yO6hFpbUM


Float: 97.65 M

Shares Outstanding: 127.26 M


Inovio Biomedical Corporation engages in the design, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The company?s SynCon technology enables the design of DNA-based vaccines capable of providing cross-protection against evolving, unmatched strains of pathogens, such as influenza. Inovio?s proprietary electroporation DNA delivery technology uses brief, controlled electrical pulses to increase cellular DNA vaccine uptake. The company also has access to formulation and manufacturing expertise, and technology through its controlling ownership in VGX International. Inovio?s clinical programs include trials for HPV/cervical cancer (therapeutic) and HIV vaccines; and an IND has been filed for an avian influenza vaccine. Its partners and collaborators include Roche,Merck, Tripep, University of Southampton, University of Pennsylvania, HIV Vaccines Trial Network, and National Microbiology Laboratory of the Public Health Agency of Canada. The company was formerly known as Genetronics Biomedical Corp. and changed its name to Inovio Biomedical Corporation in March 2005. The company was founded in 1983 and is based in San Diego, California.

Currently Inovio has 12 clinical studies ( HIV, Influenza, Malaria, Hepatitis B, Hepatitis C, Breast and Lung cancer, Prostate Cancer, Head and Neck cancer, Cervical Cancer, Cervical dysplasia caused by HPV) ongoing from preclinical to phase 2.
 
Sep 10, 2013
Roche and Inovio Pharmaceuticals partner on Inovio's prostate cancer and hepatitis B immunotherapy products. Roche will make an upfront payment of USD $10 million to Inovio. Roche will also provide preclinical R&D support and payments for near-term regulatory milestones as well as payments upon reaching certain development and commercial milestones potentially up to USD $412.5 million. Additional development milestone payments could also be made to Inovio if Roche pursues other indications with INO-5150 or INO-1800.  In addition, Inovio is entitled to receive up to double-digit tiered royalties on product sales.

VGX-3100-Phase 2 Clinical Trial initiated for the treatment Cervical dysplasia (cervical intraepithelial neoplasia or CIN) caused by HPV
Top line data release Mid 2014
May 13, 2014:  Inovio Pharmaceuticals Acquires Early Stage DNA Therapies to Treat Alzheimer's and Multiple Sclerosis
http://finance.yahoo.com/news/inovio-pharmaceuticals-acquires-early-stage-080000624.html?.tsrc=applewf

May 23, 2014: Inovio Pharmaceuticals Announces 1 For 4 Reverse Split
http://finance.yahoo.com/news/inovio-pharmaceuticals-announces-1-4-080000629.html
1-for-4 reverse stock split shall become effective at 5 P.M., Thursday, June 5, 2014, and trading of the Company's common stock on a post-reverse split basis shall commence on Friday, June 6, 2014.


Inovio’s goal is to revolutionize vaccines. With best-in-class immune responses from multiple vaccines in different disease areas, our synthetic vaccine technology is making big strides toward this important goal.



 
 



 

SureTrader
INO
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
News News Alert: Inovio’s Co-Founder along with its Lead Antigen Designer Named Among Top 20 Researchers With Most Granted U.S Patents for ... 01/17/2018 08:00:00 AM
PostSubject
#4698  Sticky Note Please stay on topic. The only topic to IH Dan (Retired) 08/02/13 01:15:33 PM
#14154   Time to load here. Easy double! $$$$ harry crumb 01/14/18 08:42:19 PM
#14153   Tax selling drove this down at the end MasterK9 01/12/18 09:41:15 AM
#14152   1/12/2018 HC Wainwright Set Price Target Buy $13.00 chmcnfunds 01/12/18 08:17:06 AM
#14151   That? arvitar 01/09/18 01:11:49 PM
#14150   This? Ubertino 01/09/18 12:56:03 PM
#14149   Really? Doesn't look like that to me. arvitar 01/09/18 10:40:14 AM
#14148   Rubber biscuit! kpisme 01/09/18 10:28:53 AM
#14147   This stock jumps around more than a monkey Ubertino 01/09/18 10:23:42 AM
#14146   Inovio Pharmaceuticals and the Parker Institute for Cancer chmcnfunds 01/09/18 09:06:11 AM
#14145   My guess is because the entire sector is chmcnfunds 01/08/18 02:06:22 PM
#14144   and yet the share price continues to go radly 01/08/18 01:23:34 PM
#14143   Inovio Receives Milestone Payment from MedImmune as MEDI0457 chmcnfunds 01/08/18 08:11:43 AM
#14142   Some know about INO, since ONCS got a avav1001 01/05/18 05:03:29 PM
#14140   Noticed the Silicon Investor website Biotech Charity Contest Cincinnatus 01/05/18 01:18:24 PM
#14139   Back in Inovio @ $4.40. No longer overbought chmcnfunds 01/05/18 11:13:11 AM
#14138   That wasn't "advice" ! arvitar 01/03/18 07:15:20 PM
#14137   Thank you! Ubertino 01/03/18 05:02:35 PM
#14136   Here's the long term view. Do the math! arvitar 01/03/18 03:16:42 PM
#14135   investorshub.advfn.com/uimage/uploads/2018/1/3/hodvjx.png arvitar 01/03/18 02:22:08 PM
#14134   Now you tell me! Just kidding. Seemed like chmcnfunds 01/03/18 08:27:49 AM
#14133   And will probably take 7 years to get radly 01/02/18 08:59:24 PM
#14132   The reasons why have been listed in this avav1001 01/02/18 03:49:35 PM
#14131   Wow, and I was trying not to cheerlead. MasterK9 01/02/18 03:38:46 PM
#14130   This Inovio is the best stock I have Ubertino 01/02/18 03:24:45 PM
#14129   Sorry to hear that. Three day rule always MasterK9 01/02/18 02:30:33 PM
#14128   Sold @ $4.60. Looking to get back when/if chmcnfunds 01/02/18 02:12:39 PM
#14126   So many good things about the agreement, sure chmcnfunds 01/02/18 10:14:10 AM
#14125   Now China....and that's where all the $$$$$$$$$$$$$$ is! Ubertino 01/02/18 09:21:46 AM
#14124   Inovio Poised For Breakthroughs In 2018 And Beyond chmcnfunds 01/02/18 09:08:02 AM
#14123   Buying opportunity according to the RSI indicator number AnonymousInvestor 12/30/17 08:24:42 PM
#14122   The INO share price falling to $4.13 on AnonymousInvestor 12/30/17 08:18:11 PM
#14121   Looks like you won't be getting in then. 7Bullet7 12/29/17 04:06:27 PM
#14120   It will continue to go lower. Looking to DrStockonomics 12/29/17 12:01:53 AM
#14119   What garbage! Lowest share price in about 4 years radly 12/28/17 07:29:19 PM
#14118   Sure not helping today: chmcnfunds 12/12/17 02:53:23 PM
#14117   Back in INO @ $4.25 on day when chmcnfunds 12/12/17 02:16:32 PM
#14116   The cure rate of HPV infection without any avav1001 12/09/17 02:49:53 AM
#14115   Placebo Question WWIII 12/08/17 04:44:39 PM
#14114   Thanks for the abstract about the synergism with avav1001 11/30/17 11:44:48 PM
#14113   I believe that is a different study. Subsequently chmcnfunds 11/30/17 08:29:57 AM
#14112   news, news and more news radly 11/29/17 09:11:31 PM
#14111   Here is the abstract of the publication. The avav1001 11/29/17 09:05:57 PM
#14110   You know I sold early, but not at chmcnfunds 11/28/17 08:36:41 AM
#14109   I agree. What the heck will it take radly 11/27/17 09:32:57 PM
#14108   This stock is unbelievable. Put out news of DrStockonomics 11/27/17 05:13:43 PM
#14107   Sold @ $4.80, far too soon, as surged chmcnfunds 11/27/17 10:19:26 AM
#14106   Inovio Pharmaceuticals SynCon® TERT Cancer Immunotherapy Combined with chmcnfunds 11/27/17 08:14:31 AM
#14105   Below 0.99 in 2018. arvitar 11/24/17 08:50:09 PM
#14104   The day they get FDA approval on any Ubertino 11/24/17 12:42:27 PM
#14103   When, in 2035? radly 11/24/17 10:15:14 AM
PostSubject